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Background: Bipolar disorder presents with diverse clinical manifestations. Numerous investigators have sought to
identify variables that may predict a more severe illness course.
Methods: With the objective of studying the clinical characteristics of bipolar patients between South and North
America, a comparison was performed between a sample from Argentina (n = 449) and a sample from the United
States (n = 503) with respect to demographics and clinical characteristics, including presence of comorbidities.
Results: The Argentinian sample had more unfavorable demographics and higher rates of prior psychiatric
hospitalization and prior suicide attempt but a better social outcome. However, the sample from the United States
had a higher rate of prior year rapid cycling, as well as younger bipolar disorder onset age (mean ± SD, 17.9 ± 8.4 vs.
27.1 ± 11.4 years) and more severe clinical morbidity, though there was no significant difference in terms of the
total duration of the illness. Argentinian compared to American patients were taking more mood stabilizers and
benzodiazepines/hypnotics, but fewer antipsychotics and other psychotropic medications, when considering
patients in aggregate as well as when stratifying by illness subtype (bipolar I versus bipolar II) and by illness onset
age (≤21 vs. >21 years). However, there was no significant difference in rate of antidepressant prescription between
the two samples considered in aggregate.
Conclusions: Although possessing similar illness durations, these samples presented significant clinical differences
and distinctive prescription patterns. Thus, though the Argentinian compared to North American patients had more
unfavorable demographics, they presented a better social outcome and, in several substantive ways, more favorable
illness characteristics. In both samples, early onset (age≤ 21 years) was a marker for poor prognosis throughout the
illness course, although this phenomenon appeared more robust in North America.
Keywords: Argentina; Bipolar disorder; Clinical characteristics; Comparative; Early onset; Onset age; Prescription
patterns; United StatesBackground
Bipolar disorder is a severe and enduring condition that
affects a significant portion of the population globally
(Weissman et al. 1996). Though specific annual rates of
occurrence can vary by geographic region of the world
(Soutullo et al. 2005), a large, international study of ten
countries revealed consistent lifetime rates of bipolar
disorder (Weissman et al. 1996). Such studies of the* Correspondence: gvazquez@palermo.edu
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in any medium, provided the original work is pAmericas, Europe, and Asia have revealed a 2.4% lifetime
prevalence of bipolar spectrum disorders (Merikangas
et al. 2011). More specifically, a 2.3% lifetime prevalence
of bipolar spectrum disorders was reported in South
American countries including Brazil and Colombia,
while a 4.4% prevalence was found in the United States
(Merikangas et al. 2011). Given the similarities in the
lifetime incidence across geographic regions of the
world, culture specific risk factors - both social and
genetic - may impact the observed cross-regional differ-
ences in the comorbidities and clinical expression of bi-
polar disorder.is an Open Access article distributed under the terms of the Creative Commons
g/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction
roperly credited.
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ical presentation of bipolar disorder, investigators have
sought to define more homogenous subgroups with the
goal of identifying genetic biomarkers, further under-
standing the neurobiology, and delineating more specif-
ically tailored, and thus more efficacious, treatment
regimens (Teixeira et al. 2013; Seifuddin et al. 2012;
Geoffroy et al. 2013).
Age at onset of bipolar disorder has been demonstrated
as a valid defining characteristic of phenotypically similar
subgroups (Strober 1992; Vázquez et al. 2011). A recent
Argentinian study found onset age significantly differenti-
ated between unipolar and bipolar affective disorders, con-
sistent with other international studies (Dervic et al. 2014;
Tondo et al. 2010). Studies have sought to identify specific
characteristics of juvenile-onset bipolar disorder (Geller
and Luby 1997). Though early-onset bipolar disorder has
been defined variably across studies and remains under-
studied in terms of specific phenotypic presentation and
treatment response, it has been consistently associated
with a more severe clinical course and comorbidities
(Leverich et al. 2007; Perlis et al. 2004; Leboyer et al.
2005). Thus, childhood-versus-adolescent-and-adult-onset
bipolar disorder has been consistently associated with
higher rates of comorbid anxiety disorder, prior suicide at-
tempt, substance and alcohol use disorders, rapid cycling,
and other validated measures of morbidity (Holtzman
et al. 2015; Rende et al. 2007; Goldberg and Ernst 2004).
Despite these consistent findings, investigators have
found that apparent rates of diagnosis of childhood
onset bipolar disorder may differ between geographic re-
gions of the world, and further that the clinical charac-
teristics of the various childhood onset groups may also
differ (Vazquez et al. 2012; Post et al. 2014). Though sev-
eral potential rationales have been proposed to explain
these differences in illness course and comorbidities, in-
cluding varying levels of psychosocial stress in childhood
and differential migration patterns according to genetic
vulnerability of affective disorders, no single theory has
been shown to possess significantly greater validity than
others (Post et al. 2014). Further, patterns of psychophar-
macological treatment, including rates of antidepressant
and benzodiazepine use, have been demonstrated to differ
significantly between European and American samples
(Post et al. 2011).
Since the advent of observationally based studies of bi-
polar disorder clinical course and characteristics, several
varying opinions regarding the respective roles of onset
age, duration of illness, and number of prior episodes
have been proposed. While some studies have proposed
illness duration as a direct measure of potential neuro-
degeneration (Frey et al. 2008), others have supported
number of prior episodes as the most accurate predictor
of longitudinal outcome (Altman et al. 2006; Goldberget al. 2005). Still other studies have suggested that onset
age is a more robust method of predicting illness course,
both due to its demonstrated efficacy in delineating
phenotypically distinct subgroups and its putative ability
to reflect common genetic characteristics (Alda et al.
2000; Azorin et al. 2013; Baldessarini et al. 2012; Etain
et al. 2012).
As such, the main objective of this study was to assess
differential clinical characteristics, comorbidities, and treat-
ment patterns between South and North American bipolar
disorder patients. Secondarily, the study sought to
identify the role of onset age in defining subgroups
with a homogenous clinical phenotype, as well as to as-
sess the specific clinical characteristics of these subpop-
ulations. We compared the clinical characteristics of
observational, naturalistic, cross-sectional data from
South and North American samples in order to assess
the consistency in illness profile of early-onset bipolar
disorder across geographic regions and to further valid-
ate onset age as a potential predictive variable of prog-
nosis in bipolar disorder.
Methods
The sample of 449 patients from Argentina consisted of
patients with bipolar I and II disorder enrolled between
2009 and 2011 in the Argentine Network on Bipolar Dis-
orders, which includes 11 tertiary-care mood disorder
clinics throughout Argentina. The sample of 503 patients
from the United States similarly consisted of patients with
bipolar I and II disorder referred to the Stanford Univer-
sity Bipolar Disorders Clinic between 2000 and 2011.
Stanford patients were enrolled in conjunction with the
Systematic Treatment Enhancement Program for Bipolar
Disorder (STEP-BD) (Sachs et al. 2002; Sachs et al. 2003).
All enrolled patients were diagnosed according to the
Diagnostic and Statistical Manual of Mental Disorders
(DSM)-IV diagnostic criteria and through semi-structured
interview (Mini International Neuropsychiatric Interview
(MINI) and Structured Clinical Interview for DSM for
mood disorders). The protocols for subject enrollment were
approved by the local Institutional Review Board (Stanford
University Administrative Panel on Human Subjects) of
each center. Subjects provided both verbal and written
informed consent prior to enrollment and participation.
Assessment of onset age was based on patient retro-
spective recall of the first occurrence of a syndromal
hypomanic, manic, mixed, or major depressive episode.
Comparative variables were selected based upon clin-
ical characteristics and comorbidities that were fre-
quently reviewed in other similar observational studies
of bipolar disorder (Baldessarini et al. 2012; Leboyer et al.
2005; Geoffroy et al. 2013). An index of clinical morbidity
was calculated by dividing the log-transformed lifetime
number of mood episodes by the log-transformed years of
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explained in a previous work, a composite measure of so-
cial outcome was computed, weighting social variables as
follows: being employed (10 points), currently being mar-
ried (5 points), and having completed high school (1 point)
(Baldessarini et al. 2012).
Comorbidities and clinical characteristics were defined
in terms of lifetime presence, except in the cases of the
history of substance use disorder and history of anxiety
disorder in the Argentinian sample. These two variables
were defined as the current presence at the time of
interview in the Argentinian sample in comparison with
the lifetime presence in the sample from the United
States.
Statistical analyses were completed using R software ver-
sion 3.0.1 (R Foundation, Vienna, Austria). Specific com-
parative analyses included chi-square test comparisons for
categorical variables and unpaired t-test comparisons of
continuous variables. In the case of a non-normally distrib-
uted variable, a non-parametric test, namely the Wilcoxon-
Mann-Whitney test, was performed. An F-test was used to
compare the variances of the onset age distributions be-
tween the two samples. Multivariate logistic and linear re-
gression modeling were used to assess whether differences
in clinical characteristics remained significantly different
upon controlling for demographic factors, including
gender, education, marital status, occupational status, and
clinical factors, including bipolar subtype and onset age.Table 1 Demographics and clinical characteristics of bipolar d
Argentina (
Demographics
Age at Intake (years) [mean ± SD] 45.1 ± 13.0**
Females [%,(n)] 65.0 (292)*
Single [%,(n)] 61.1 (274)**
Unemployed [%,(n)] 32.6 (146)*
Less than 8 years of education [%,(n)] 19.1 (86)****
Social Outcome [mean ± SD] 9.3 ± 3.2****
Clinical characteristics
Bipolar I [%,(n)] 54.9 (247)*
Early onset (≤21 years) [%,(n)] 38.6 (173)**
Prior year rapid cycling [%,(n)] 12.4 (56)****
Prior suicide attempt [%,(n)] 45.7 (205)**
Prior psychiatric hospitalization [%,(n)] 55.0 (247)**
Substance use disorder [%,(n)]d 11.0 (49)****
Anxiety disorder [%,(n)]a 10.7 (48)****
Age at onset (years) [mean ± SD] 27.1 ± 11.4**
Illness duration (years) [mean ± SD] 17.8 ± 11.8
Morbidity index 0.78***
Number of psychotropic medications [mean ± SD] 2.5 ± 1.0
aDiscrepancy in measures, as described in ‘Methods’ section. *p < 0.05; **p < 0.01; **Further, multivariate logistic regression modeling was used
to assess the differential rates of psychotropic medication
usage by subtype (mood stabilizer, antipsychotic, anti-
depressant, benzodiazepine/hypnotic, and other medica-
tion) across nationalities, controlling for onset age, age at
enrollment, illness duration, gender, total social outcome,
and diagnostic subtype.
Results
We studied Argentinian (n = 449) and North American
(n = 503) bipolar I and II patients that visited a variety of
psychiatric hospitals throughout Argentina or who were
referred to the Stanford Bipolar Disorders Clinic in sub-
urban Northern California. The Argentinian study par-
ticipants were 65.0% female, with a mean age of 45.1 ±
13.0 years, and 32.6% were unemployed. The study par-
ticipants from the United States were 58.3% female, with
a mean age of 35.6 ± 13.3 years, and 39.8% were un-
employed (Table 1). Accordingly, total social outcome
was found to be better in the Argentinian sample as
compared to the North American sample (9.3 ± 3.2 vs.
8.2 ± 5.9, p = 0.0001).
In terms of clinical characteristics and comorbidities,
the two samples differed significantly, as well. Patients
from Argentina compared to the United States had a
higher rate of having bipolar I disorder (54.9% vs. 48.3%,
p = 0.04). In the North American population, as demon-
strated by the almost 10 years earlier mean onset ageisorder patients in Argentina and the United States
n = 449) United States (n = 503) Total (n = 952)
** 35.6 ± 13.3 40.0 ± 13.2
58.3 (293) 61.4 (585)
** 36.1 (182) 47.9 (456)
39.8 (200) 36.3 (346)
1.4 (7) 9.8 (93)
8.2 ± 5.9 8.7 ± 4.8
48.3 (243) 51.5 (490)
** 78.3 (394) 59.6 (567)
36.2 (182) 25.0 (238)
** 30.8 (155) 37.8 (360)
** 37.8 (190) 45.9 (437)
44.5 (224) 28.7 (273)
64.8 (326) 39.3 (374)
** 17.9 ± 8.4 22.3 ± 10.8
17.6 ± 8.4 17.7 ± 10.2
0.87 0.83
2.6 ± 1.7 2.6 ± 1.4
*p < 0.001; ****p < 0.0001 versus United States.
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ficantly greater proportion of patients had an onset age
of less than or equal to 21 years of age (78.3% vs. 36.6%,
p < 0.0001). Accordingly, a greater percentage of the
Argentinian sample presented with late onset (>40 years)
than the North American sample (14.3% vs. 2.6%, p <
0.0001). Further, the variances of the onset age distri-
butions were significantly different between the two
samples (F = 1.7, p < 0.0001) (Figure 1). The sample from
the United States also had significantly higher rates of
comorbid anxiety disorder (64.8% vs. 10.7, p < 0.0001),
comorbid substance use disorder (44.5% vs. 11.0%,
p < 0.0001), and prior year rapid cycling (36.2% vs.
12.4%, p < 0.0001), as well as a greater morbidity (t = 3.8,
df = 889, p = 0.0002). Conversely, the sample from
Argentina had higher rates of prior suicide attempt
(45.7% vs. 30.8%, p < 0.0001) and history of psychiatric
hospitalization (55.0% vs. 37.8%, p < 0.0001). However,
as noted above, no significant difference was found be-
tween Argentina and the United States in terms of the
mean illness duration (17.8 ± 11.8 vs. 17.6 ± 8.4 years,
p = 0.83) or the mean number of psychotropic medica-
tions (2.5 ± 1.0 vs. 2.6 ± 1.7, p = 0.57). Thus, significant
differences at an alpha level of 0.05 were found be-
tween the samples for all of the demographics and ill-
ness characteristics in Table 1, except for mean illness
duration and mean number of psychotropic medica-
tions. Using a Bonferroni-corrected p-value of 0.003,
most of the abovementioned demographic and clinical
differences remained significant.
In a comparison of the early-onset subsets (≤21 years
of age), the Argentinian sample again showed better
social outcomes (9.0 ± 3.5 vs. 7.9 ± 5.9, p = 0.03) and
higher rates of prior psychiatric hospitalization (57.5% vs.
34.9%, p < 0.0001), bipolar I disorder (56.4% vs. 44.3%,
p = 0.01), and prior suicide attempt (54.7% vs. 34.3%,Figure 1 Histogram of bipolar disorder onset ages in Argentina and
the United States. Green indicates onset ages in Argentina. Red
indicates onset ages in the United States. *p < 0.0001 for difference
in means and variances of onset age distributions for Argentina
versus United States.p < 0.0001) (Table 2). Conversely, the sample from the
United States again showed higher levels of prior year
rapid cycling (40.5% vs. 20.5%, p = 0.002), substance use
disorder (59.8% vs. 14.6%, p < 0.0001), anxiety disorder
(69.0% vs. 11.0%, p < 0.001), and overall clinical morbidity
(t = 4.0, df = 360, p < 0.0001) and morbidity index (0.88 vs.
0.75, t = 3.8, df = 889, p < 0.0001). There was no demon-
strated difference between the Argentinian and North
American samples in terms of the mean number of psy-
chotropic medications (2.6 ± 1.0 vs. 2.6 ± 1.7, p = 0.73).
Finally, the patterns of results differed substantively in
a comparison of unfavorable illness characteristics be-
tween early (age ≤21 years) and later onset within the
Argentinian and North American samples (Figures 2
and 3). Within the Argentinian sample, the early-onset
cohort was only shown to have significantly higher rates
of prior year rapid cycling (20.5% vs. 6.9%, p = 0.01) and
prior suicide attempt (54.7% vs. 40.7%, p = 0.005). For all
of the other observed variables, the early-onset cohort
demonstrated only non-significantly greater rates of un-
favorable illness characteristics. In contrast, within the
North American sample, significant differences in the
rates of unfavorable illness characteristics were demon-
strated for all of the observed variables. In all character-
istics except bipolar I subtype (44.3% vs. 63.3%, p =
0.0007) and prior psychiatric hospitalization (34.9% vs.
48.6%, p = 0.01), the early-onset cohort demonstrated a
more severe phenotype, including history of anxiety dis-
order (69.0% vs. 50.5%, p = 0.0005), history of substance
use disorder (59.8% vs. 39.4%, p = 0.0002), history of
more than nine lifetime mood episodes (47.5% vs. 18.9%,
p < 0.0001), prior year rapid cycling (40.5% vs. 20.0%,
p = 0.0002), and prior suicide attempt (34.3% vs. 17.9%,
p = 0.002).
Prescription patterns between the United States and
Argentina were computed in aggregate as well as when
stratifying by illness subtype (bipolar I vs. bipolar II) and
by illness onset age (≤21 vs. >21 years). Independent of
stratification by potential confounding demographic and
illness characteristics, the Argentinian compared to the
American sample was found to be taking significantly
more mood stabilizers and benzodiazepines/hypnotics,
and significantly fewer antipsychotics and other psycho-
tropic medications. No significant differences in terms of
antidepressant use were found between the two national-
ities when considered in aggregate. Analysis of prescrip-
tion patterns between Argentina and the United States
explored within subdivisions of bipolar subtype indicated
that among patients with bipolar I disorder, rates of pre-
scription of all five medication subgroups differed signifi-
cantly (Figure 3a), whereas among patients with bipolar II
disorder, rates of prescription of all medication classes ex-
cept antidepressants differed significantly (Figure 3b). The
consistency of the abovementioned prescribing patterns
Table 2 Demographics and illness characteristics in early-onset (≤21 years) subsets of bipolar disorder patients in
Argentina and the United States
Argentina (n = 172) United States (n = 393) p value for difference
Demographic characteristics
Age at intake (years) [mean ± SD] 39.1 ± 13.0 33.3 ± 12.2 <0.0001
Female [%,(n)] 66.7 (115) 58.5 (230) 0.30
Single [%,(n)] 67.6 (116) 33.7 (132) <0.0001
Unemployed [%,(n)] 25.8 (44) 40.2 (158) 0.001
Less than 8 years of education [%,(n)] 19.4 (33) 1.5 (6) <0.0001
Social outcome [mean ± SD] 9.0 ± 3.5 7.9 ± 5.9 0.03
Clinical characteristics and comorbidities
Bipolar I [%,(n)] 56.4 (97) 44.3 (174) 0.01
Prior year rapid cycling [%,(n)] 20.5 (35) 40.5 (160) 0.002
Prior suicide attempt [%,(n)] 54.7 (94) 34.3 (135) <0.0001
Prior psychiatric hospitalization [%,(n)] 57.5 (99) 34.9 (137) <0.0001
Substance use disorder [%,(n)]a 14.6 (25) 59.8 (235) <0.0001
Anxiety disorder [%,(n)]a 11.0 (19) 69.0 (271) <0.0001
Illness duration (years) [mean ± SD] 21.9 ± 12.9 18.9 ± 13.3 0.01
Morbidity index 0.75 0.88 <0.0001
Number of psychotropic medications [mean ± SD] 2.6 ± 1.0 2.6 ± 1.7 0.73
aDiscrepancy in measures, as described in ‘Methods’ section.
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sion model, controlling for onset age, age of enrollment,
illness duration, gender, total social outcome, and diagnos-
tic subtype. Across both illness subtypes, Argentinian
compared to North American patients had significantly
higher rates of taking mood stabilizers and benzodiaze-
pines/hypnotics and significantly lower rates of taking an-
tipsychotics and other medications.
Upon performing multivariate logistic regression ana-
lyses controlling for demographic characteristics as well
as bipolar subtype, all differences in clinical characteris-
tics between the populations were found to persist.
Discussion
Overall, the two samples of bipolar patients derived from
Argentina and the United States differed significantly not
only in terms of demographic characteristics but also in
terms of clinical features. Despite the similar sample sizes,
the Argentinian sample had many more unfavorable de-
mographic characteristics, including lower marriage rates
and less years of education. It is worth noting that almost
20% of individuals had not completed primary education.
Such low levels of education may warrant a more careful
examination of the effects of bipolar disorder on the at-
tainment and sustainment educational opportunities, as
well as further development of programs to support social
engagement for individuals with severe mental illness.
However, when a cumulative measure of social outcome
was computed, the Argentinian sample demonstrated amore favorable social outcome. A recent study found that
married women with bipolar disorder had lower cumula-
tive illness severity and fewer prior mood episodes than
never-married women with bipolar disorder, suggesting
that patients may be sensitive to the beneficial effects of
social support (Lieberman et al. 2010). As such, promoting
a positive social environment for individuals with bipolar
may support positive therapeutic outcomes.
In addition to the demographic characteristics, the two
populations also differed significantly with regard to clin-
ical characteristics. In terms of bipolar disorder onset age,
almost 80% of the North American population presented
with onset at less than or equal to 21 years of age, in con-
trast in the Argentinian population, only 40% of patients
presented with such an early onset. This relevant differ-
ence in distribution of onset age as a categorical parameter
was consistent with the nearly 10-year difference in mean
onset age as a continuous parameter between the two
samples. Also consistent with the difference in mean onset
age, onset in later adulthood, defined as after 40 years of
age, was substantially more prevalent in the Argentinian
sample. Some investigators have proposed that a late-
onset phenotype of bipolar disorder may represent a dif-
ferent etiological pathway, favoring organic brain disease
over family history of mood disorder (Almeida and Fenner
2002). However, proponents of this theory noted that few
clinical differences appear between the earlier- and later-
onset groups, and that those present are potentially due to
differences in illness duration (Baldessarini et al. 2012).
Figure 2 Illness characteristics in early- (≤21 years) compared to later-onset patients in Argentina and the United States. (A) Illness characteristics
by onset age among patients in Argentina. (B) Illness characteristics by onset age among patients in the United States. *p < 0.05; **p < 0.01;
***p < 0.001; ****p < 0.0001 for onset age≤21 versus >21 years.
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ferences with respect to unfavorable illness characteristics.
The lower onset age seen in the Stanford compared to
Argentinian cohort has been associated with multiple un-
favorable illness characteristics. Indeed, the Stanford co-
hort compared to Argentinian cohort had a significantly
higher morbidity index and significantly higher rates of
prior year rapid cycling, substance use disorder, and anx-
iety disorder (although methodological differences could
have also contributed to the latter two comorbidity differ-
ences). Although the significantly lower rate of bipolar I
disorder could account for the Stanford compared to
Argentinian cohort significantly less often having a history
of prior psychiatric hospitalization, the potential factors
contributing to the Stanford compared to Argentiniancohort having a significantly lower rate of prior suicide at-
tempt remains to be established.
It is possible that the significant demographic and bipo-
lar subtype differences between the two samples contrib-
uted substantively to the observed clinical differences. For
instance, bipolar I disorder and psychiatric hospitalization,
as well as bipolar II disorder and rapid cycling, are com-
monly highly correlated, and as such, the different rates of
bipolar subtypes between the samples could have con-
tributed substantively to these observed differences. The
higher rate of prior year rapid cycling in the Stanford com-
pared to Argentinian cohort (36.2% vs. 12.4%) could be re-
lated to the higher rate of early onset (≤21 years) in the
Stanford compared to Argentinian cohort (78.3% vs.
38.6%). However, the difference in rates of prior year rapid
Figure 3 Medication patterns by nationality and bipolar subtype. (A) Comparative medication patterns in bipolar I disorder. (B) Comparative
medication patterns in bipolar II disorder. *p < 0.05; **p < 0.01; ***p < 0.001; ****p < 0.0001 for Argentina versus United States.
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pressant administration, which was similar across the two
cohorts.
Nevertheless, upon performing multivariate logistic re-
gression analyses controlling for demographic character-
istics as well as bipolar subtype, all differences in clinical
characteristics between the populations were found to
persist. The results of these regression analyses suggest
that the observed differences in clinical characteristics,
including rates of prior psychiatric hospitalization, prior
year rapid cycling, prior suicide attempt, anxiety dis-
order, substance use disorder, and current medication
utilization were not simply a reflection of differences in
demographic characteristics and bipolar subtype be-
tween the national samples.
In our study, despite the significant differences in
demographic and clinical characteristics (including onset
age), there was no difference in illness duration betweenthe samples from Argentina and the United States. This
finding supports a greater role of onset age than illness
duration in determining the severity of the illness
course. However, substantial controversy remains as to
the respective roles of onset age and illness duration in
the determination of prognosis among bipolar disorder
patients. Some studies seeking to identify clinical stages
in bipolar disorder by determining combinations of pre-
dictive factors have found that there was no difference
in mean illness duration between groups identified with
‘good’ versus ‘poor’ outcomes (Reinares et al. 2013).
However, other studies have found illness duration to be
inversely correlated with the likelihood and speed of re-
covery (Peters et al. 2014) as well as with gray matter
volume, suggesting a potential neurodegenerative pro-
gression of bipolar disorder across the clinical course
(Frey et al. 2008). Though the role of illness duration in
the determination of potential neuroprogression has not
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set age as a more significant predictor of poor illness
course than total illness duration.
An exploration of the rates of current usage of dif-
ferent medication subtypes revealed interesting, highly
significant differences in the patterns of prescription be-
tween the two samples. Even when controlling for po-
tential clinical and demographic differences between the
two samples that could contribute substantively to ob-
served differences in medication patterns, Argentinians
compared to North Americans were more often taking
mood stabilizers and benzodiazepines/hypnotics and less
often taking antipsychotics. Such differences may reflect
significant trans-national variations in the prescription
of different types of medications for the treatment of the
same disorder.
Given documented differences in treatment patterns by
bipolar subtype, we were interested to further explore
whether differences in medication patterns appeared
within bipolar I and bipolar II subgroups (Ghaemi et al.
2006). This analysis revealed that the significant differ-
ences between national patterns of medication indeed per-
sisted upon dividing the Argentinian and North American
samples by bipolar subtype. As such, it can be suggested
that the observed transnational differences in rates of pre-
scription of the medication subgroups reflected actual dif-
ferences in treatment patterns as opposed to differences in
the distribution of bipolar subtype. Further exploration of
the therapeutic implications of different treatment regi-
mens is warranted. Investigating differential rates of recur-
rence between the populations as a measure of functional
outcome with different treatment regimens could provide
interesting insights into the comparative effectiveness of
various medication subtypes in the treatment of bipolar
disorder.
In addition to the comparison between the entire
Argentinian and North American samples, we performed
a more specific comparison between only the subgroups
with early onset, defined as occurring at less than or equal
to 21 years of age. Early onset has consistently been asso-
ciated with a worse illness course (Leverich et al. 2007); as
such, comparing the two groups with the worst prognosis
was thought to have the potential to reveal notable differ-
ences between the populations. A majority of the same
demographic differences observed for the entire groups
persisted between the early-onset subgroups, though in
some instances to a lesser degree of significance. Even
when controlling for differences in demographic charac-
teristics and bipolar subtype, the Argentinian patients with
early onset were found to have been previously hospi-
talized for psychiatric treatment and have prior suicide
attempt more often. In contrast, the North American
individuals presented with more severe clinical morbidity,
higher rates of prior year rapid cycling, history ofsubstance use disorders, and history of anxiety disorder.
As such, individuals with early onset in neither Argentina
nor the United States presented consistently with a worse
illness course; each group presented with more and less
severe clinical characteristics in differing aspects.
In performing comparisons between sites, particularly
between different countries, it must be noted that not
every clinical characteristic was measured in a consistent
manner. In this study, there was a discrepancy in the
measurement of rates of comorbid anxiety and sub-
stance use disorders. Though both groups used the same
diagnostic criteria, the Argentinian site defined this vari-
able as the current presence of anxiety or substance
abuse disorders at the time of interview, while the North
American site used a definition of lifetime presence of
an anxiety or substance use disorder. Therefore, though
the direct comparison of these rates between national-
ities may have validity limitations, the overall rate of
comorbidity within each sample and the comparison
within each nationality between onset-age groups may
still be of interest. Specifically, it is worth noting that al-
most 45% of the patients from the United States suffered
at one point in their lives from a comorbid substance
use disorder. Further, almost 65% of the North American
cohort had a comorbid anxiety disorder prior to enroll-
ment in the study. More investigation is warranted to
analyze the rates of these comorbidities within sub-
groups of bipolar patients so as to assess the potential
inclusion of these characteristics in diagnostic criteria
(Vazquez et al. 2014).
Lastly, a comparison was performed, within each na-
tional group, between individuals with early (≤21 years)
versus later (>21 years) onset of bipolar disorder to de-
termine whether onset age was a reliable predictor of
unfavorable illness characteristics in both Argentina and
the United States. In the North American sample, early
onset was more robustly associated with the presence of
comorbidities and unfavorable illness characteristics
compared to the later-onset group. The early-onset sub-
set presented significantly higher rates of comorbid anx-
iety disorder, substance abuse disorder, prior year rapid
cycling, and prior suicide attempt, as well as a significantly
greater portion of the sample with at least ten lifetime
mood episodes. In contrast, the later-onset group had
higher rates of bipolar I and of psychiatric hospitalization.
Previous findings have varied as to the relationship be-
tween bipolar subtype and age at onset, reflecting varying
differences in age at illness presentation (Benazzi 1999).
Onset age within the North American sample therefore
consistently differentiated distinct illness profiles.
However, within the Argentinian sample, such a broad
pattern of significant differences in the prevalence un-
favorable illness characteristics was not revealed. The
early-onset group showed significantly elevated rates of
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Importantly, these onset-age-related differences persisted
between the groups when controlling for bipolar sub-
type, suggesting that these differences were not simply a
reflection of the distinctive clinical presentation of the
two bipolar subtypes. The other traits that were examined
did not reveal significant differences in the rate of occur-
rence between early- and later-onset groups, though the
early-onset group did show non-significantly elevated rates
of each characteristic. It is possible that these differences
were non-significant due to a lack of statistical power,
given that only 172 Argentinian patients presented with
early onset in comparison to 393 North American pa-
tients, though this is an unlikely explanation as seen by
the highly similar rates between onset-age groups in the
Argentinian sample. Given the apparent difference in the
relevance of onset age as a predictor of distinct illness
course, it is necessary to consider individual sample char-
acteristics before utilizing onset age as a predictive vari-
able. Despite the differential relevance of onset age in
predicating the severity of comorbidities between the two
samples, onset age appears to be a relatively robust vari-
able for identifying a more severe illness course.
This study possesses numerous strengths, including a
substantial number of patients, use of validated assess-
ment instruments, and use of largely consistent mea-
sures across sites. Further, when the significance of
results was re-computed using a Bonferroni correction
for multiple comparisons, most of the observed differ-
ences remained significant. However, our analysis also
had noteworthy limitations, several of which are typical
of observational and comparative studies. First, selection
bias may have been introduced into the study due to
the significant demographic differences between the two
sites, although the impacts of such differences were lim-
ited by use of regression analyses that covaried for
demographic differences. The Bipolar Disorder Clinic at
Stanford University is a tertiary-care private clinic in
suburban Northern California. The patient population
has relatively high socioeconomic and educational levels.
In contrast, the patients from Argentina were enrolled at
both public and private psychiatric hospitals and clinics
that generally had lower socioeconomic and educational
levels. Therefore, our cross-national comparison findings
may be limited by socioeconomic differences, although
the persistence of clinical differences in the analyses that
covaried for demographic and illness subtype differences
make this potential limitation less problematic. Despite
the demographic differences, it is of note that both the
South and North American samples consisted solely of
outpatients.
Further, the results of this study should be interpreted
carefully, noting that such findings cannot be assumed
to uniformly represent the state of the entire countriesof Argentina or the United States. Not only did the two
samples differ from one another but they are also not re-
flective of the overall demographic makeup of the two
countries either. As such, the differences between the
samples are presented as a means to highlight the varia-
tions in clinical presentation between the two study
samples but not necessarily as a means to represent the
residents of a country as a whole.
Additionally, as with most studies of this kind, the defin-
ition of onset age was determined by retrospective recall
rather than in a prospective manner. Therefore, a potential
degree of uncertainty may have been introduced into the
samples due to the effects of recall bias, though it is im-
portant to note that onset age in both studies was deter-
mined in the same manner. The determination of age at
onset may also be affected in part by the extent of delay to
diagnosis following onset of mood symptoms, which may
differ by region of the world (Wang et al. 2007) but was
not measured in either of the samples; for this reason,
onset age was defined as the first recalled occurrence of
syndromic mood dysregulation, rather than the age at
diagnosis or initiation of treatment. Similarly, the validity
of retrospectively recalled number of lifetime mood
episodes was augmented by assessing it as a categorical
variable (<9 lifetime mood episodes), rather than as a con-
tinuous variable.
Conclusions
The bipolar samples from Argentina and the United States
differed significantly with respect to several demographic
and clinical characteristics. Broadly, the Argentinian sam-
ple tended to have more unfavorable demographic charac-
teristics, while the North American sample presented with
in several substantive ways more unfavorable illness char-
acteristics (in spite having more favorable demographic
characteristics). Despite these specific differences, both
samples presented important and distinctive challenges
for diagnosis and treatment. In order to address these
challenges, onset age may be a valid and robust measure
for identifying a more severe illness course, though the
specific characteristics of each sample must be taken into
account. Specifically, onset in youth may be earlier and
may have more robust associations with unfavorable ill-
ness characteristics in North compared to South America.
Further study is warranted to determine the extent to
which onset age should be used in the international con-
text as a defining characteristic for more homogenous
subgroups within bipolar disorder.
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